BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 20551839)

  • 21. Dendritic cells in melanoma immunotherapy.
    Faries MB; Czerniecki BJ
    Curr Treat Options Oncol; 2005 May; 6(3):175-84. PubMed ID: 15869729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human CD141
    Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
    Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
    Front Immunol; 2021; 12():623639. PubMed ID: 33692796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy and experimental approaches for metastatic melanoma.
    Atkins MB
    Hematol Oncol Clin North Am; 1998 Aug; 12(4):877-902, viii. PubMed ID: 9759585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
    Geskin LJ; Damiano JJ; Patrone CC; Butterfield LH; Kirkwood JM; Falo LD
    Melanoma Res; 2018 Jun; 28(3):211-221. PubMed ID: 29543704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A role of immunotherapy in metastatic malignant melanoma.
    Allen T; Gundrajakuppam L
    Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):182-8. PubMed ID: 22697295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward prediction of immune mechanisms and design of immunotherapies in melanoma.
    Tsoka S; Ainali C; Karagiannis P; Josephs DH; Saul L; Nestle FO; Karagiannis SN
    Crit Rev Biomed Eng; 2012; 40(4):279-94. PubMed ID: 23140120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.
    Barker CA; Postow MA
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):986-97. PubMed ID: 24661650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
    Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
    Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status of melanoma vaccines.
    Kuhn CA; Hanke CW
    Dermatol Surg; 1997 Aug; 23(8):649-54; discussion 654-5. PubMed ID: 9256911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma.
    Marshall JA; Forster TH; Purdie DM; Lanagan CM; O'Connor LE; O'Rourke MG; Johnson MK; See JL; Ellem KA; Martinez NR; López JA; Schmidt CW
    Immunol Cell Biol; 2006 Jun; 84(3):295-302. PubMed ID: 16681827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of malignant melanoma.
    Kadison AS; Morton DL
    Surg Clin North Am; 2003 Apr; 83(2):343-70. PubMed ID: 12744613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment approaches for advanced cutaneous melanoma.
    Stein JA; Brownell I
    J Drugs Dermatol; 2008 Feb; 7(2):175-9. PubMed ID: 18335655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for advanced melanoma.
    Fang L; Lonsdorf AS; Hwang ST
    J Invest Dermatol; 2008 Nov; 128(11):2596-2605. PubMed ID: 18927541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on immunotherapy for melanoma.
    Ribas A
    J Natl Compr Canc Netw; 2006 Aug; 4(7):687-94. PubMed ID: 16884670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanoma immunotherapy.
    Sanlorenzo M; Vujic I; Posch C; Dajee A; Yen A; Kim S; Ashworth M; Rosenblum MD; Algazi A; Osella-Abate S; Quaglino P; Daud A; Ortiz-Urda S
    Cancer Biol Ther; 2014 Jun; 15(6):665-74. PubMed ID: 24651672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Future of malignant stage I melanoma. Immunology and immunotherapy].
    Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP
    Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.